Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem

Authors: Bhavnani SM, Hammel JP, Cirincione B, Wikler MA, Ambrose PG
Publication: Antimicrob Agents Chemother
Keywords: administration & dosage, adolescent, adult, aged, bacteria, bacterial infections, biological, Carbapenems, doripenem population, double-blind method, drug effects, female, humans, infusions, intravenous, male, Microbial Sensitivity Tests, microbiology, middle-aged, models
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Abstract

A doripenem population pharmacokinetic model and Monte Carlo simulations were utilized for dose regimen decision support for future clinical development. Simulation results predict that 500 mg of doripenem administered over 1 h every 8 h would be effective against bacterial strains with MICs less than 2 microg/ml and that less susceptible strains could be treated with prolonged infusions.

By, Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG